



Thomas Noesslinger

Contact

Thomas Noesslinger

Publications (2)

Fürstenau M, Thus Y, Robrecht S, Mellink C, van der Kevie-Kersemaekers A, Dubois J, von Tresckow J, Patz M, Gregor M, Thornton P, Staber P, Tadmor T, Levin M, da Cunha-Bang C, Schneider C, Poulsen C, Illmer T, Schöttker B, Janssens A, Christiansen I, Noesslinger T, Baumann M, Hebart H, Gaska T, Regelink J, Dompeling E, Lindstrom V, Juliusson G, Widmer A, Goede J, Goldschmidt N, Simon F, De Silva N, Fink A, Fischer K, Wendtner C, Ritgen M, Brüggemann M, Tausch E, Spaargaren M, Eldering E, Stilgenbauer S, Niemann C, Hallek M, Eichhorst B, Kreuzer K, Kater A. High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations. *Blood* 2023

Eichhorst B, Niemann C, Kater A, Fürstenau M, von Tresckow J, Zhang C, Robrecht S, Gregor M, Juliusson G, Thornton P, Staber P, Tadmor T, Lindstrom V, da Cunha-Bang C, Schneider C, Poulsen C, Illmer T, Schöttker B, Noesslinger T, Janssens A, Christiansen I, Baumann M, Frederiksen H, Klift M, Jäger U, Leys M, Hoogendoorn M, Lotfi K, Hebart H, Gaska T, Koene H, Enggaard L, Goede J, Regelink J, Widmer A, Simon F, De Silva N, Fink A, Bahlo J, Fischer K, Wendtner C, Kreuzer K, Ritgen M, Brüggemann M, Tausch E, Levin M, van Oers M, Geisler C, Stilgenbauer S, Hallek M, GCLLSG, the HOVON and Nordic CLL Study Groups, the SAKK, the Israeli CLL Association, and Cancer Trials Ireland. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia. *N Engl J Med* 2023; 388:1739-1754.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch